Correction [0.03%]
改正通知
Published Erratum
Oncoimmunology. 2025 Dec 31;14(1):2600808. DOI:10.1080/2162402X.2025.2600808 2025
HLA class-I genotyping to personalize Bacille Calmette-Guerin immunotherapy in bladder cancer [0.03%]
HLA-I分型个性化卡介苗膀胱癌免疫治疗
Inmaculada Ruiz-Lorente,Lourdes Gimeno,Alicia López-Abad et al.
Inmaculada Ruiz-Lorente et al.
Bacille Calmette-Guerin (BCG) is the immunotherapy of choice for high-risk non-muscle invasive bladder cancer (BC), although recurrence eventually occurs in 50% of patients and 20% progress to advanced stages. This study evaluates the predi...
Miguel A Moreno-Gonzalez,Jessica Fernanda Affonso de Oliveira,Manuel L Penichet et al.
Miguel A Moreno-Gonzalez et al.
Our laboratory specializes in the intratumoral (i.t.) delivery of virus nanoparticles (VNPs) that activate immune cells and modulate the tumor microenvironment (TME). For this study, we conjugated the CH401 peptide-containing B-cell, helper...
Prostate tumor immune microenvironment changes following immunotherapy shared by patients who developed anti-tumor response or immune-related adverse events [0.03%]
接受免疫治疗后发生抗肿瘤反应或免疫相关不良事件的前列腺癌患者肿瘤免疫微环境变化相似性分析
Ichwaku Rastogi,Douglas G McNeel
Ichwaku Rastogi
Checkpoint inhibitors targeting PD-1/PD-L1 have revolutionized cancer immunotherapy, yet their efficacy in prostate cancer has been limited. We previously reported a clinical trial (NCT02499835) evaluating PD-1 blockade combined with an ant...
Disruption of CD91 association with AXL and Fgr abrogates HSP-mediated signaling and cancer immunosurveillance [0.03%]
CD91与AXL和Fgr的相互作用被破坏后，HSP介导的信号转导和癌症免疫监视被消除
Trey Harkness,Abigail L Sedlacek,Keya Shah et al.
Trey Harkness et al.
CD91 serves as a receptor that causes the activation of antigen-presenting cells in response to cancer cells by binding HSPs. In this context, the HSP-CD91 axis is responsible for the rejection of emerging and nascent cancers. The role of C...
Serum Arginase-1 is a predictive biomarker for melanoma patients and a surrogate indicator of systemic myeloid cell fitness [0.03%]
血清精氨酸酶-1是黑色素瘤患者的预测性生物标志物，也是全身髓样细胞功能的替代指标
Matthias Brand,Juraj Adamik,Hong Wang et al.
Matthias Brand et al.
While recent advances in immuno-oncology have revolutionized cancer therapy, only a subset patients benefit from these treatments and achieve durable clinical responses. Biomarker-guided identification of patients likely to respond to immun...
Clinical Trial
Oncoimmunology. 2025 Dec 31;14(1):2595764. DOI:10.1080/2162402X.2025.2595764 2025
Deubiquitinating enzyme JOSD2 modulates cGAS to facilitate immune evasion in colorectal cancer [0.03%]
脱泛素酶JOSD2通过调节cGAS促进结直肠癌免疫逃逸
Jiamin Du,Yiqun Fan,Junwei Fu et al.
Jiamin Du et al.
Colorectal cancer (CRC) remains a formidable clinical challenge, many patients exhibit limited responses to conventional chemotherapy and targeted therapies. Although immunotherapy has demonstrated potential, its efficacy is largely restric...
Wnt3a-expressing cancer stem cells impair CD8+ TRM function, contributing to immunotherapy resistance in Melanoma [0.03%]
黑色素瘤中Wnt3a阳性癌症干细胞损害CD8+TRM功能导致免疫治疗耐药性产生
Julián A Gajón,Angel Juarez-Flores,Fatima Mendoza-Roldan et al.
Julián A Gajón et al.
Immune checkpoint blockade (ICB) has revolutionized the treatment of advanced malignancies such as melanoma. However, a significant proportion of patients fail to respond, owing to mechanisms that remain poorly understood. Here, we develope...
IGF2BP1 fosters an immunosuppressive tumor microenvironment in high-risk neuroblastoma, contributing to their resistance to immunotherapy [0.03%]
IGF2BP1通过促进高危神经母细胞瘤免疫抑制性肿瘤微环境的形成，使其产生免疫治疗抵抗性
Mayura R Dhamdhere,Chethana P Gowda,Yuka Imamura et al.
Mayura R Dhamdhere et al.
The incorporation of the current immunotherapy, GD2-targeting monoclonal antibodies, into the standard of care has moderately improved clinical outcomes in children with high-risk neuroblastoma (HR-NB); however, overall survival remains low...
FDA approves lurbinectedin in combination with atezolizumab for extensive-stage small cell lung cancer [0.03%]
美国FDA批准lurbinectedin与atezolizumab联合用于广泛期小细胞肺癌
Oliver Kepp,Guido Kroemer
Oliver Kepp
The recent FDA approval of lurbinectedin plus atezolizumab for advanced small cell lung cancer underscores the promise of combining immunogenic cell death (ICD) inducers with PD-1/PD-L1 blockade. This synergistic strategy induces durable re...